logo

Protalix Biotherapeutics Inc. (PLX)



Trade PLX now with
  Date
  Headline
8/26/2021 6:51:39 AM Protalix BioTherapeutics Announces Closing Of 7.50% Senior Secured Convertible Notes Due 2021 Exchange
8/16/2021 6:58:13 AM Protalix BioTherapeutics Q2 Net Loss $11.2 Mln Or $0.25/Shr Vs Loss Of $4.2 Mln Or $0.13/Shr Last Year
8/2/2021 6:51:29 AM Protalix BioTherapeutics Announces Submission Of Type A Meeting Request To FDA For Pegunigalsidase Alfa
5/14/2021 6:52:40 AM Protalix BioTherapeutics Q1 Loss/Shr $0.14 Vs EPS $0.10 Last Year
4/28/2021 1:52:09 AM Protalix BioTherapeutics And Chiesi Global Rare Diseases Receive CRL For Pegunigalsidase Alfa From FDA
3/30/2021 6:53:03 AM Protalix BioTherapeutics FY20 Net Loss $6.5 Mln Or $0.22/Shr Vs Loss $18.3 Mln Or $1.23/Shr Last Year
2/23/2021 6:52:32 AM Protalix BioTherapeutics And Chiesi Global Rare Diseases Announce Positive Topline Results From BRIGHT Phase III Trial
2/18/2021 8:04:11 AM Protalix BioTherapeutics Completes Raise Of About $40 Mln In Gross Proceeds
2/11/2021 9:21:17 PM Protalix BioTherapeutics Prices Public Offering Of 7.61 Mln Shares At $4.60/shr
2/11/2021 6:51:41 AM Protalix Partners With SarcoMed To Develop Alidornase Alfa For Pulmonary Sarcoidosis And Respiratory Diseases
12/30/2020 6:52:46 AM Protalix BioTherapeutics Says Continued To Seek Multiple Collaborative Partnerships To Complement Core Platform
12/30/2020 6:50:00 AM Protalix BioTherapeutics Issues 2020 Letter to Shareholders (Press Release)